Transparent Safety Monitoring

FDA-compliant post-market surveillance with full transparency. Every adverse event tracked, reported, and resolved publicly.

All Systems Operational

No serious adverse events reported. All recent reports resolved within SLA. Last update: December 17, 2024

Safety Dashboard

Real-time monitoring across all Openwater devices

127 Days Since Last Incident
📊
8 Reports This Quarter
⏱️
3.2 Avg Resolution (Days)
🎯
100% Resolved Within SLA

Recent Safety Reports

Last 90 days of adverse event tracking

Minor #SR-2024-008

Device Connectivity Issue During Setup

Device: OpenLIFU Gen 2

Event Date: Dec 10, 2024

Status: Resolved

User reported difficulty connecting device to institutional network during initial setup. No patient impact. Resolved through updated network configuration guide and IT support training.

View Full Report →
Moderate #SR-2024-007

Transient Discomfort During Treatment

Device: OpenLIFU Gen 2

Event Date: Nov 15, 2024

Status: Resolved

Patient reported mild headache during ultrasound treatment session. Symptoms resolved within 2 hours without intervention. Protocol adjusted to include gradual intensity ramp-up for first-time patients. No long-term effects observed in 30-day follow-up.

View Full Report →
Minor #SR-2024-006

Software Update Notification Delay

Device: OpenMOTION v3.0

Event Date: Oct 28, 2024

Status: Resolved

Delayed notification of available software security update. No data breach or patient impact. Notification system enhanced with redundant channels (email + in-app + SMS).

View Full Report →

Quarterly Safety Summaries

Comprehensive reports submitted to FDA

Q4

Q4 2024 Safety Summary

8 reports filed (6 minor, 2 moderate, 0 serious). All resolved within 7-day SLA. Protocol improvements implemented for patient comfort. Zero serious adverse events.

Download Full Report (PDF) →
Q3

Q3 2024 Safety Summary

5 reports filed (4 minor, 1 moderate, 0 serious). Software stability improvements deployed. Enhanced user training materials developed.

Download Full Report (PDF) →
Q2

Q2 2024 Safety Summary

11 reports filed (9 minor, 2 moderate, 0 serious). Network connectivity documentation improved. Clinical site IT support protocols established.

Download Full Report (PDF) →
Q1

Q1 2024 Safety Summary

3 reports filed (3 minor, 0 moderate, 0 serious). Early deployment phase with limited sites. All issues resolved through documentation updates.

Download Full Report (PDF) →

FDA Compliance & MAUDE Integration

Meeting federal requirements for post-market surveillance

📋 Regulatory Compliance

All adverse events are reported to the FDA through the MAUDE (Manufacturer and User Facility Device Experience) database within required timelines. Serious events reported within 30 days, malfunctions within 5 business days. Full transparency maintained through this public registry.

⏱️

7-Day SLA

Internal review & resolution target

📊

Quarterly Reports

Comprehensive FDA submissions

🔔

Community Alerts

Immediate notification system

Report a Safety Event

Help us maintain the highest safety standards. All reports are confidential and contribute to continuous improvement.

Submit Safety Report →